Solana (SOL) price surges 10% to $89, breaking triangle pattern. ETF inflows hit $40M, with analysts eyeing $100-$110 targets as Bitcoin rebounds above $67K.
Browsing: News
XRP climbs 9% to $1.46 as whale accumulation increases. Analysts eye $1.50 resistance level as key trigger for potential move toward $2 and beyond.
Ethereum’s new Strawmap roadmap outlines plans for 2-second blocks, quantum resistance, 10K TPS on L1, and seven protocol forks over four years.
Ethereum (ETH) breaks above $2,000 with 15% rally. ETF inflows exceed $20M, Foundation stakes 70K ETH, and $893M options expire Friday. Full analysis.
Bitcoin retreated from $70K while altcoins surged. Nvidia earnings beat expectations but shares faded. Analysis of crypto and stock market trends on Feb 26.
Jane Street faces federal lawsuit over alleged insider trading in Terra Luna’s $40B collapse and separate ban from Indian markets over manipulation claims.
Bitcoin (BTC) surged 7% after Jane Street was sued over Terra’s collapse. Traders speculate the firm stopped its alleged daily 10 a.m. sell algorithm.
Microsoft (MSFT) stock jumped 2.5% on Starlink Kenya partnership news, 299M global connections, Xbox hardware teases, and Strong Buy analyst ratings.
Tempus AI (TEM) stock declines as JPMorgan slashes price target to $60. Q4 revenue surges 83% but profitability timeline remains unclear for investors.
Revolut explores 2026 share sale at $100B+ valuation before potential $150B IPO. The fintech begins testing a pound-pegged stablecoin with UK regulators.
Coinbase (COIN) stock surged 13% after introducing zero-commission stock and ETF trading with 24/5 availability for U.S. investors on February 24.
Intel (INTC) stock has surged 90% in a year to $46, trading at 112x earnings. EBITDA expected to reach $25.1B by 2028. Analysts divided on future outlook.
XWELL (XWEL) stock rallies 250% after revealing $31.3M private placement deal with American Ventures to repurchase debt and redeem preferred stock.
Axon Enterprise (AXON) stock jumped 18% after crushing Q4 earnings expectations with $797M revenue and strong 2026 guidance exceeding analyst projections.
RBC Capital Markets initiates AbbVie (ABBV) with outperform rating and $260 price target, citing Skyrizi/Rinvoq growth and undervalued EPS at 16x earnings.